BioCentury
ARTICLE | Company News

Alexion prices Strensiq, plans to use voucher itself

October 27, 2015 12:02 AM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said the average annual U.S. price of Strensiq asfotase alfa will be $285,000, with weight-based dosing and other factors taken into account. EVP and CFO Vikas Sinha announced the price during a conference call Monday. The company expects Strensiq to be available to patients by Tuesday.

FDA approved Strensiq on Friday to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP). The therapy is a fusion protein incorporating the catalytic domain of human tissue non-specific alkaline phosphatase ( TNSALP; ALPL) and a bone-targeting peptide (see BioCentury Extra, Oct. 23). ...